Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to

Feng-Shiun Shie1, Kathleen S Montine, Richard M Breyer

  • 1Department of Pathology, University of Washington, Seattle 98104, USA.

Brain Pathology (Zurich, Switzerland)
|May 26, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APOE4 Drives Uniquely Dysfunctional Human Microglial States in Alzheimer's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Potential glutamatergic and GABAergic false neurotransmitters in models of excitation-inhibition imbalance.

Scientific reports·2026
Same author

Astrocytic FKBP5 regulates neuroinflammation and cognitive outcomes in male mouse models of excitotoxic epilepsy.

Brain, behavior, and immunity·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

PGE<sub>2</sub>/EP3/CXCR2 Axis Dictates Amplified Inflammatory Response during Skin Infection in Mice with Obesity.

The Journal of investigative dermatology·2025
Same author

Epigenomic profile of GBA1 in Parkinson's disease.

Parkinsonism & related disorders·2025

Targeting the EP2 receptor in microglia may offer a novel therapeutic strategy for Alzheimer's disease (AD). This approach enhances the removal of amyloid-beta plaques while reducing neurotoxicity, unlike traditional NSAIDs.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Prostaglandin pathway involvement in Alzheimer's disease (AD) pathogenesis is supported by epidemiological and animal data.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting cyclooxygenase (COX) have shown unexpected toxicity, necessitating alternative therapeutic targets within the prostaglandin pathway.
  • Previous research demonstrated that EP2 receptor knockout (EP2-/-) mice are protected from neurotoxicity linked to innate immune responses.

Purpose of the Study:

  • To review data supporting the microglial EP2 receptor as a focused therapeutic target for Alzheimer's disease.
  • To evaluate the combined effects of EP2 receptor deficiency on neurotoxicity and amyloid-beta (Abeta) phagocytosis in microglia.

Main Methods:

  • Review of existing data on EP2 knockout mice and their response to Abeta exposure.

Related Experiment Videos

  • Analysis of microglial function, specifically neurotoxicity and Abeta phagocytosis, in EP2-/- models.
  • Examination of Abeta peptides in synthetic forms and human brain deposits.

    • Main Results:

    • EP2-/- microglia exhibit reduced indirect neurotoxicity upon exposure to Abeta(1-42).
    • EP2-/- microglia demonstrate enhanced phagocytosis of both synthetic and deposited Abeta peptides.
    • These findings highlight a dual benefit of targeting the EP2 receptor.

    Conclusions:

    • Microglial EP2 receptor is a promising, focused therapeutic target within the prostaglandin pathway for AD.
    • Targeting microglial EP2 offers a potential strategy to mitigate Abeta-induced neurotoxicity and improve Abeta clearance in AD.
    • This approach may overcome the limitations and toxicity associated with conventional NSAIDs in AD treatment.